Becton Dickinson and Company ($BDX) Stock Forecast: Up 6.2% Today

What is Becton Dickinson and Company?

Becton, Dickinson and Company (BDX) is a healthcare company that has recently experienced a bullish market movement.

Why is Becton Dickinson and Company going up?

BDX stock is up 6.2% on Feb 11, 2026 18:56

• BDX stock exhibited a strong bullish trend despite its underperformance compared to the broader market and healthcare sector ETFs in the previous year.
• Initially facing a decline due to a notable miss in life sciences revenue, the stock later recovered following the surpassing of Q4 2025 revenue and EPS estimates.
• Analysts' consensus rating of "Moderate Buy" and a mean price target indicating an expected 18.8% increase likely influenced the bullish movement.
• The optimistic outlook may also stem from investors' confidence in BDX's growth opportunities and strategic efforts to tackle industry challenges.

BDX Price Chart

BDX Technical Analysis

BDX News

Are Wall Street Analysts Bullish on Becton, Dickinson and Company Stock?

Becton, Dickinson and Company (BDX) has underperformed the broader market and healthcare sector ETFs over the past year. Despite beating Q4 2025 revenue and EPS estimates, the stock dropped due to a significant miss in life sciences revenue. Analysts currently hold a "Moderate Buy" consensus, with a mean price target suggesting an 18.8% upside.

https://markets.financialcontent.com/stocks/article/barchart-2026-2-11-are-wall-street-analysts-bullish-on-becton-dickinson-and-company-stock

Waters Corporation $WAT Stock Holdings Decreased by Madison Asset Management LLC

Madison Asset Management LLC reduced its stake in Waters Corporation (NYSE:WAT) by 1.5% in the third quarter, while institutional ownership remains high at 94.01%. Despite beating Q4 earnings estimates, Waters experienced share weakness due to Q1 2026 guidance falling below street expectations. Analysts hold a "Moderate Buy" rating, with an average target price of $400.84, although some firms adjusted targets due to integration risks with BD’s Biosciences & Diagnostic Solutions.

https://www.marketbeat.com/instant-alerts/filing-waters-corporation-wat-stock-holdings-decreased-by-madison-asset-management-llc-2026-02-11/

Gram Staining Systems Market Is Going to Boom |• Thermo Fisher Scientific • Merck KGaA

Worldwide Market Reports has published a comprehensive study on the "Gram Staining Systems Market Size and Forecast 2026-2033," analyzing growth drivers, opportunities, restraints, and challenges. The report utilizes primary and secondary research, including SWOT analysis and Porter's Five Forces, to provide insights into market dynamics, competitive landscapes, and regional performance. It covers detailed market segmentation, key players like Thermo Fisher Scientific and Merck KGaA, and growth forecasts across various regions and applications.

https://www.openpr.com/news/4386528/gram-staining-systems-market-is-going-to-boom-thermo-fisher

STERIS Restructuring And Deals Test Earnings Strength And Dividend Resolve

STERIS (NYSE:STE) is undergoing restructuring and making strategic acquisitions to adapt to the evolving medical technology and sterilization sectors. These efforts aim to enhance operational flexibility and reinforce its market position, with investors closely watching execution and integration. Despite significant corporate changes, STERIS continues to report strong sales and earnings, maintaining its quarterly dividend, suggesting a balanced approach to growth and shareholder returns.

https://simplywall.st/stocks/us/healthcare/nyse-ste/steris/news/steris-restructuring-and-deals-test-earnings-strength-and-di

Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency

Quest Diagnostics (DGX) is transforming its business by aggressively pivoting towards advanced diagnostics and AI-driven efficiency, leading to a fresh 52-week high for its shares. This shift, combined with a strong fourth-quarter earnings report and a legislative reprieve on Medicare reimbursement rates, positions Quest as a critical "lab engine" in the evolving healthcare landscape, particularly in precision medicine. The company is focusing on innovations like AD-Detect for Alzheimer's and Haystack MRD for cancer monitoring, while also streamlining operations through "Project Nova" and navigating competitive and regulatory challenges.

https://markets.financialcontent.com/stocks/article/finterra-2026-2-11-quest-diagnostics-dgx-navigating-the-new-frontier-of-advanced-diagnostics-and-ai-efficiency

Trending Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.1% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.1% Today

Deere & Company ($DE) Stock Forecast: Up 11.6% Today

ZCash ($ZEC) Crypto Forecast: Down 8.4% Today

Pool Corporation ($POOL) Stock Forecast: Down 13.6% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.4% Today

Cadence Design Systems Inc. ($CDNS) Stock Forecast: Down 5.7% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.7% Today

Garmin Ltd. ($GRMN) Stock Forecast: Down 0.0% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

Becton Dickinson and Company Price History

11.01.2026 - BDX Stock was up 6.2%

• BDX stock exhibited a strong bullish trend despite its underperformance compared to the broader market and healthcare sector ETFs in the previous year.
• Initially facing a decline due to a notable miss in life sciences revenue, the stock later recovered following the surpassing of Q4 2025 revenue and EPS estimates.
• Analysts' consensus rating of "Moderate Buy" and a mean price target indicating an expected 18.8% increase likely influenced the bullish movement.
• The optimistic outlook may also stem from investors' confidence in BDX's growth opportunities and strategic efforts to tackle industry challenges.

11.01.2026 - BDX Stock was up 5.2%

• BDX stock had a strong bullish movement.
• Market reacted positively to BDX's strategic focus on high-growth areas as a "Pure-Play MedTech" company.
• Investors are optimistic about BDX's long-term value creation potential despite short-term concerns over revised earnings guidance for 2026.
• Market may be favorably viewing BDX's restructuring efforts and strategic positioning, driving the bullish movement in the stock price.

05.00.2026 - BDX Stock was up 1.9%

• BDX experienced a strong bullish movement today, likely driven by positive developments.
• A major financial institution raised the price target for BDX shares, indicating confidence in the company's performance and potential upside.
• Recent innovations and advancements such as the first Phasix™ Mesh laparotomy reinforcement case in Greece and progress in the PREVENT clinical trial showcase BD's dedication to improving patient outcomes, potentially contributing to positive investor sentiment.
• An additional $10 million share repurchase program was announced, signaling the company's confidence in its financial position and commitment to returning capital to shareholders, which may have bolstered investor confidence in BDX.

04.01.2026 - BDX Stock was up 2.8%

• BDX saw a notable increase in its stock price today, following the reception of three 2026 Best in KLAS Awards for its medication management technologies. These awards underscore the company's industry leadership and positive feedback from healthcare professionals.
• The strategic decision by Becton, Dickinson and Company to restructure its business by spinning off its Biosciences & Diagnostic Solutions division and merging it with Waters Corporation likely contributed to investor confidence and propelled the stock price upwards.
• Despite Mediolanum International Funds Ltd reducing its holdings in BDX, other institutional investors making adjustments to their positions did not detract from the overall positive outlook on the company.
• Analysts raised the price target for BDX, emphasizing upcoming segment transitions and the company's investments in expanding production capabilities, which further bolstered investor confidence in the stock's future growth prospects.

07.07.2025 - BDX Stock was up 7.4%

• BDX stock experienced a strong bullish movement today.
• The company surpassed Q3 earnings and revenue estimates, indicating strong financial performance.
• Despite expectations of declining earnings, BDX managed to deliver positive surprises, boosting investor confidence.
• The better-than-expected performance in key metrics for the quarter ended June 2025 likely contributed to the bullish market movement.

06.10.2025 - BDX Stock was down 0.8%

• Despite surpassing expectations for earnings and revenue in the quarter, BDX witnessed a decline in its stock value.
• The market's reaction might be linked to uncertainties regarding the company's future growth trajectory or provided guidance.
• Investors could be considering broader factors like global economic conditions or developments within the industry, impacting the stock's downward trend.
• The bearish movement could also be influenced by profit-taking activities or prevailing market sentiment, potentially overshadowing the positive earnings outcome.

25.08.2025 - BDX Stock was down 3.9%

• The bearish movement in BDX stock could be attributed to profit-taking by investors after a recent bullish run.
• The initiation of coverage on Biogen (NASDAQ: BIIB) on a bullish note may have diverted attention and funds away from BDX temporarily.
• Market analysts changing their outlook on top names could have influenced investor sentiment towards BDX, leading to the bearish movement.
• Overall, the market movement in BDX today may be a short-term correction influenced by external factors rather than any fundamental issues with the company itself.

10.01.2026 - BDX Stock was down 17.3%

• BDX reported strong Q1 2026 earnings but lowered its full-year guidance, leading to a bearish market sentiment.
• Analysts revised their price targets downwards following the adjusted earnings guidance, contributing to the stock's significant decline.
• Despite a positive outlook on the "new company" and potential upside, the market reacted negatively to the lowered profit guidance due to the sale/spin-off of its Biosciences & Diagnostic Solutions unit.
• The bearish movement of BDX shares was also influenced by the broader market sentiment towards medical technology firms, as seen in the performance of other companies facing challenges with earnings misses and conservative revenue guidance.

23.00.2026 - BDX Stock was down 5.0%

• BDX faced a bearish market movement despite positive third-quarter results, increased dividend, and strong FY2026 EPS guidance.
• The sale of SmartDose rights by a pharmaceutical services company to another entity could have impacted BDX's market sentiment negatively, leading to the bearish movement.
• The launch of BD Research Cloud 7.0 with AI-powered tools for immunology and cancer research, while positive for BD's long-term growth, might not have been enough to offset the overall market sentiment impacting the stock price.
• Investors may have reacted cautiously to the news, potentially waiting for more clarity on how these developments will translate into revenue growth and market competitiveness for BDX in the future.

10.01.2026 - BDX Stock was down 19.0%

• BDX shares fell by 3% after the company lowered its profit outlook for fiscal year 2026, following the completion of the spin-off of its biosciences & diagnostic solutions business which merged with Waters in a $17.5bn agreement.
• An analyst adjusted BDX's price target downwards to $170 from $205, maintaining a Neutral rating, reflecting a shift in the outlook.
• Waters (WAT) received a favorable rating and a $400 price target from an analyst after acquiring BDX's Life Sciences Bioprocessing segment, positioning itself well in the medical diagnostics and research market.
• Despite BDX reporting stronger-than-expected Q1 FY2026 results with profits of $5.25bn, the revised profit outlook and analyst rating adjustments contributed to the bearish movement in the stock today.

10.01.2026 - BDX Stock was down 14.9%

• A financial institution lowered its price target for BDX and maintained a "buy" rating, citing a reduction in profit guidance for FY26 due to the sale/spin-off of a unit, leading to a drop in share price.
• Another financial institution adjusted BDX's price target downwards and maintained a Neutral rating, reflecting a shift in outlook by analyst firms.
• Despite positive sentiment from an industry expert towards the company's recent developments, the market reacted negatively to the lowered profit guidance and revised price targets by multiple analyst firms.
• The bearish movement in BDX's stock could be attributed to the mixed Q4 2025 results reported by another company, which also impacted the broader sentiment in the healthcare sector.

10.11.2025 - BDX Stock was up 2.8%

• An investment firm increased Becton Dickinson's price target to $220 from $215 and maintained a Buy rating, citing positive implications from a transaction with Waters Corporation. This adjustment reflects optimism about the company's future performance.
• The global Pharmacy Automation Systems Market is projected to grow significantly, with key players like BD poised to benefit from the increasing adoption of automation in healthcare.
• Solventum Corporation, a healthcare company spun off from 3M, is garnering attention for its potential turnaround story, which could indirectly impact positively on companies like Becton, Dickinson and Co.
• Despite a reduction in stake by Natixis, institutional investors still hold a significant portion of Becton, Dickinson and Co.'s stock, indicating continued confidence in the company's prospects.